

BIOSANTE PHARMACEUTICALS INC  
Form 8-K  
March 01, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

**Current Report**

**Pursuant to Section 13 or 13(d) of the Securities Exchange Act of 1934**

---

Date of Report (Date of earliest event reported):

**March 1, 2013**

**BIOSANTE PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or Other Jurisdiction of  
Incorporation)

**001-31812**  
(Commission File Number)

**58-2301143**  
(I.R.S. Employer Identification  
Number)

**111 Barclay Boulevard**

**Lincolnshire, Illinois**  
(Address of Principal Executive Offices)

**60069**  
(Zip Code)

**(847) 478-0500**

Edgar Filing: BIOSANTE PHARMACEUTICALS INC - Form 8-K

(Registrant's Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Section 2 Financial Information**

**Item 2.02. Results of Operations and Financial Condition.**

On March 1, 2013, BioSante Pharmaceuticals, Inc. publicly announced its financial results for the year ended December 31, 2012. For further information, please refer to the news release attached hereto as Exhibit 99.1, which is incorporated by reference herein.

**Section 8 Other Events**

**Item 8.01. Other Events.**

On March 1, 2013, BioSante provided an update regarding its proposed merger with ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc.

A copy of the press release is filed as Exhibit 99.1 to this report and is incorporated herein by reference.

**Section 9 Financial Statements and Exhibits**

**Item 9.01. Financial Statements and Exhibits.**

(d) *Exhibits.*

<b>Exhibit No.</b>	<b>Description</b>
99.1	News Release issued March 1, 2013

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BIOSANTE PHARMACEUTICALS, INC.**

By: */s/ Phillip B. Donenberg*  
Phillip B. Donenberg  
*Senior Vice President of Finance, Chief Financial  
Officer and Secretary*

Dated: March 1, 2013

**BIOSANTE PHARMACEUTICALS, INC.**

**FORM 8-K**

**Exhibit Index**

<b>Exhibit No.</b>	<b>Description</b>	<b>Method of Filing</b>
99.1	News Release issued March 1, 2013	Filed herewith